dromostanolone-propionate and Breast-Neoplasms

A randomized trial was done in 98 post-menopausal women with breast cancer. Hormonal receptors had not been assayed in any patient. Patients were given hormonal therapy with tamoxifen and drostanolone propionate (n = 34), or chemotherapy with the CMF protocol (n = 30), or a combination of both (n = 34). The results are in favour of hormonal therapy alone, which gave the best immediate objective responses, the least adverse side-effects, and possibly improved survival rates.

Topics: Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Random Allocation; Receptors, Estrogen; Tamoxifen

Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Androstanols; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Drug Evaluation; Female; Humans; Middle Aged; Remission Induction

After diagnostic hormonal treatment of 129 patients, 11 (8.5%) were revealed to have breast cancer. The diagnostic accuracy in the case of a lesion of less than 1.0 cm in diameter was 11.8% for palpation, 18.2% for mammography, 33.3% for ultrasonography; the accuracy of this method is 66.6%. Minimal breast cancer was present in eight out of nine cases. Thus, diagnostic hormonal treatment was found to be useful in the diagnosis of minimal breast cancer that coexists with mastopathy.

Topics: Adult; Androstanols; Breast; Breast Neoplasms; Female; Fibrocystic Breast Disease; Floxuridine; Humans; Mammography; Palpation; Ultrasonography

5-Fluorouracil (5-FU) and 2 alpha-methyldihydrotestosterone propionate (MDTP) have effectively induced complete regressions of induced rat mammary carcinomas; in combination, regressions were additive and synergistic. Present aims were to determine whether similar antitumor effects were obtainable with a human mammary carcinoma, MCF-7, and to affirm the synergism of 5-FU and MDTP. After incubation in vitro for 3 days and exposure to drug for another 2 days, cell counts and/or determinations of total cell protein revealed growth inhibitions of 16-87% by 5-FU at 130-1300 micrograms/ml and 16-94% by MDTP at 0.36-360.5 micrograms/ml. Combinations of 5-FU and MDTP at the same inhibitory doses (ID) yielded approximately additive growth inhibitions. Algebraic and geometric (isobole) methods of analyses showed that these inhibitions were additive or synergistic, depending on the iso-effective dose used. Precursor incorporation into macromolecules also showed approximately additive effects for MCF-7 cells treated with 5-FU and MDTP, each at ID15. These data demonstrate significant additive growth-inhibitory activity of 5-FU and MDTP in combination against MCF-7 in vitro, thus affirming their antitumor effects in vivo.

Topics: Androstanols; Breast Neoplasms; Cell Division; Cell Line; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans